Fusion Pharmaceuticals Inc., a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that it has entered into a clinical trial collaboration with a subsidiary of Merck (known as MSD outside the U.S. and Canada) to evaluate Fusion's lead candidate, [²²⁵Ac]-FPI-1434 (FPI-1434), in combination with Merck's anti-PD-1 (programmed death receptor-1) therapy, KEYTRUDA® (pembrolizumab), in patients with solid tumors expressing insulin-like growth factor 1 receptor (IGF-1R).

The planned Phase 1/2 combination trial will evaluate safety, tolerability and pharmacokinetics of FPI-1434 in combination with pembrolizumab and is expected to initiate approximately six to nine months after achieving the recommended Phase 2 dose in the ongoing Phase 1 study of FPI-1434 monotherapy. Under the terms of the agreement, Fusion will sponsor the study and Merck will supply KEYTRUDA.

To read more please visit:

https://ir.fusionpharma.com/2021-05-06-Fusion-Pharmaceuticals-Announces-Clinical-Collaboration-with-Merck-to-Evaluate-Fusions-Targeted-Alpha-Therapy-TAT-in-Combination-with-Mercks-KEYTRUDA-R-pembrolizumab-in-Patients-With-Solid-Tumors-Expressing-IGF-1R

Source: Fusion Pharmaceuticals Inc.